Endorsements by Ronak H Shah

0000-0001-9042-6213

Senior Manager, Computational Biologist, Center of Molecular Oncology, Memorial Sloan Kettering Cancer Center
Manager, Computational Biologist, Cmo operation, Sloan Kettering Institute
Director, Bioinformatics, Pediatric Gentics, Feinstein Institute for Medical Research, Northwell Health
Principal Computational Biologist, Department of Pathology, Memorial Sloan Kettering Cancer Center
Bioinformatics Application Developer, Monsanto Co
Research Assistant, Georgetown University
Master's in Bioinformatics & Computational Biology, George Mason University
B.Tech Bioinformatics, D.Y.Patil University
Bioinformatics, Genomics, Cancer, Assembly

My Website

Google Scholar

synapse.mskcc.org

Endorsements

A Reproducible Data Analysis Workflow with R Markdown, Git, Make, and Docker
exciting
All endorsers

Own works

Data from Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
All endorsers
Data from Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
All endorsers
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
All endorsers
Supplementary Figures 1 from Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
All endorsers
Supplementary Figures 1 from Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
All endorsers
Supplementary Tables 1 from Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
All endorsers
Supplementary Tables 1 from Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
All endorsers
Serial Cell-Free DNA Sequencing in ROS1 Fusion–Positive Lung Cancers During Treatment With Entrectinib
All endorsers
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
All endorsers
High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer
All endorsers
Targeting HER2 mutant advanced biliary tract cancers with neratinib: results from the SUMMIT ‘basket’ trial
All endorsers
Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights
All endorsers
Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing
All endorsers
<p>Precision oncology: lessons learned and challenges for the future</p>
All endorsers
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.
All endorsers
Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability
All endorsers
Real-time genomic characterization of metastatic pancreatic neuroendocrine tumors has prognostic implications and identifies potential germline actionability
All endorsers
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
All endorsers
Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
All endorsers
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
All endorsers
Clinical and genetic determinants of ovarian metastases from colorectal cancer
All endorsers
Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma.
All endorsers
Next-generation sequencing (NGS) in pancreatic neuroendocrine tumors (panNETs): Defining differentiation and grade genetically.
All endorsers
Abstract 2419: Anastomotic recurrences are clonally related to primary tumors in sporadic colorectal carcinoma
All endorsers
The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes
All endorsers
Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid
All endorsers
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
All endorsers
Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma.
All endorsers
Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid
All endorsers
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
All endorsers
Impact-Sv: A Perl Based Framework To Call, Annotate Structural Variants Using Delly And Dranger
All endorsers
iAnnotateSV: Cosmic Count Annotation
All endorsers
iCallSV: Updated codebase to work with new version of iAnnotateSV
All endorsers
Alternative transcription initiation leads to expression of a novel ALK isoform in cancer
All endorsers
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
All endorsers
Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2)
All endorsers
MP36-12 CLONALITY OF BLADDER TUMORS FOLLOWING RADICAL NEPHROURETERECTOMY – AGAINST THE FIELD DEFECT HYPOTHESIS
All endorsers
MP7-13 GENETIC SIGNATURES ARE ASSOCIATED WITH ADVERSE PATHOLOGIC AND CLINICAL OUTCOMES IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA (UTUC)
All endorsers
Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma
All endorsers
Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder
All endorsers
Genomic Characterization of Upper Tract Urothelial Carcinoma
All endorsers
IMPACT-Pipeline: First Pre-Release to run MSK-IMPACT framework
All endorsers
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
All endorsers
Abstract LB-91: SMARCA4 mutations in small cell carcinoma of the ovary
All endorsers
Recurrent SMARCA4 mutations in small cell carcinoma of the ovary
All endorsers
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions
All endorsers
Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing
All endorsers